The Asia Pacific Rapid Diagnostics Market is emerging as one of the rapidly growing segments within the global diagnostics sphere, fueled by escalating healthcare demands, increasing disease prevalence, heightened awareness regarding early detection, and major technological progress. Rapid diagnostics, or point-of-care testing, deliver swift, reliable results without the necessity for intricate laboratory setups—an essential benefit in numerous areas of Asia Pacific where rural communities and neglected populations may have limited access to centralized healthcare institutions. The need for prompt diagnosis of both chronic and infectious ailments has positioned rapid diagnostic tools at the forefront of healthcare provision in the area. One of the primary drivers for market expansion in the Asia Pacific region has been the escalated demand for quick testing solutions during public health crises, especially during the COVID-19 pandemic. Nations such as India, China, Japan, South Korea, and Southeast Asian countries experienced a rise in the uptake of rapid antigen and antibody tests for widespread screening and surveillance. This not only broadened the market in terms of volume but also underscored the potential of rapid diagnostics in enhancing health outcomes and managing future outbreaks. Following the pandemic, the focus on preparedness, decentralized healthcare, and disease management has continued to fuel investments in diagnostic infrastructure and innovation.
Asia Pacific Rapid Diagnostics will grow by 10.9% annually with a total addressable market cap of $ 129,373.7 million over 2022-2031. Infectious diseases remain a significant issue throughout the region, particularly in tropical and low-income nations. Conditions like malaria, dengue, tuberculosis, hepatitis, and HIV are still widespread in many locations, reinforcing the necessity for economical, rapid, and accessible diagnostic solutions. Governments and international health organizations are progressively incorporating rapid diagnostics into national healthcare strategies and public health initiatives to effectively tackle these challenges. Furthermore, the rising incidence of non-communicable diseases such as diabetes, cardiovascular issues, and cancer is further stimulating the demand for rapid diagnostic testing that can facilitate ongoing monitoring and early intervention. Technological advancements are crucial in influencing the Asia Pacific rapid diagnostics market. From lateral flow assays to smartphone-compatible biosensors and portable molecular platforms, the region is experiencing a spike in product innovation and local production. Countries like China, India, and South Korea are emerging as significant manufacturing centers, reducing dependency on imported diagnostic kits and devices. Simultaneously, regional governments are improving regulatory frameworks and investing in healthcare digitization to promote the extensive implementation of diagnostic technologies in both urban and rural areas.
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
The Asia Pacific Rapid Diagnostics Market is influenced by the healthcare advancements and contributions of numerous key countries and regions, each playing an essential part in market growth, technology implementation, and public health efforts. China emerges as a prominent market leader because of its large population, expanding middle class, and strong government emphasis on enhancing healthcare infrastructure. During the COVID-19 pandemic, China significantly increased its production of rapid diagnostic kits and testing instruments, becoming not only a vital consumer but also a key global exporter. Ongoing investment in biotech innovation and domestic manufacturing further bolsters its position in the regional market. India is another crucial player, characterized by high demand for rapid tests in urban and rural healthcare environments. The government’s extensive health initiatives, such as Ayushman Bharat and the National Health Mission, have integrated rapid diagnostic testing to enhance disease surveillance and early intervention, especially for tuberculosis, malaria, and diabetes. India additionally supports a growing number of local diagnostics manufacturers that cater to both national and international markets. Japan and South Korea make substantial contributions to the region’s innovation and technological progress in diagnostics. These nations feature highly developed healthcare systems and robust R&D capabilities. Their input is particularly significant in the areas of molecular diagnostics and digital health integration, where precision, speed, and user experience are emphasized. In Southeast Asia, countries like Thailand, Indonesia, Malaysia, and the Philippines are witnessing an increase in demand for rapid testing due to heightened healthcare awareness and the necessity to address endemic diseases such as dengue, HIV, and hepatitis. Public health initiatives and NGO-led programs have been instrumental in improving access to diagnostic tools in these nations.
Based on Product, the Asia Pacific rapid diagnostics market is divided into Consumables and Analyzers/Instruments. Consumables represent the largest share of revenue because of their recurring nature and widespread application in various diagnostic fields, including glucose monitoring, infectious disease assessment, and pregnancy testing. As the prevalence of diseases increases and healthcare services expand in rural and semi-urban areas, the need for test strips, reagents, and cartridges is consistently growing. Analyzers and instruments, while generally requiring a higher initial investment, are crucial for both professional and decentralized testing environments. These consist of portable and benchtop devices that provide more accurate result interpretation, especially in hospitals and advanced care settings. From 2021 to 2031, both product categories are anticipated to grow steadily, with consumables remaining dominant, particularly as more home-based and point-of-care solutions are introduced to the market. Based on Prescription, the Asia Pacific market is divided into Professional Diagnostics and OTC-Based Testing. Professional diagnostics represent the largest portion of the market, driven by the needs of hospitals, clinics, and laboratories where trained professionals perform tests for diseases such as tuberculosis, hepatitis, and cancer. These diagnostics offer high accuracy and reliability, which are essential for making medical decisions. Simultaneously, OTC-based testing is quickly gaining traction as individuals increasingly opt for self-testing kits for glucose monitoring, pregnancy detection, and COVID-19 testing. The growth of this segment is propelled by rising health awareness, better product availability, and the convenience of testing at home. Regulatory support and a growing acceptance of telehealth are also helping OTC diagnostics to become a key component of preventive healthcare throughout the region. From 2021 to 2031, OTC testing is expected to expand at a quicker rate, reshaping the diagnostic landscape of the region.
By Platform, the Asia Pacific market comprises Immunoassays, Molecular Detection, and Other Platforms. Immunoassays are the leading segment, with Lateral Flow Assays being the most commonly used, especially for pregnancy, COVID-19, and dengue testing due to their user-friendly nature and quick results. Serological assays are becoming increasingly popular for antibody detection in post-infection monitoring, while other immunoassays such as ELISA are utilized in clinical laboratories. Molecular detection technologies, especially Polymerase Chain Reaction (PCR), are esteemed for their accuracy and have experienced a significant rise in usage during the pandemic. Other molecular tests, including loop-mediated isothermal amplification (LAMP), are emerging for point-of-care applications. Other platforms—like biosensors and microfluidics—are slowly entering the market, backed by regional innovations. From 2021 to 2031, molecular detection is expected to experience substantial growth due to its expanding applications in infectious disease and cancer diagnostics. By Application, the rapid diagnostics market in the Asia Pacific covers various use cases. Blood glucose testing occupies the largest share owing to the increasing diabetes prevalence in the region. Cardiometabolic testing is on the rise as disorders related to lifestyle become more prevalent. Infectious disease testing represents a significant segment, which includes COVID-19, HAI, Hepatitis, Tropical Diseases, HIV, Influenza, STD, and Other Infections, all of which require quick, accessible solutions. The region's susceptibility to outbreaks enhances the need for rapid diagnostics. Blood coagulation and hematology testing aid chronic disease management, while cancer testing benefits from growing awareness and early detection initiatives. Drug abuse testing is experiencing higher demand in the realms of occupational health and law enforcement. Pregnancy and fertility testing continue to be high-volume applications available over the counter. Other applications, such as allergy and thyroid testing, are expanding as consumers look for wider self-monitoring options. Overall, from 2021 to 2031, growth is fueled by urbanization, disease patterns, and better access to care. By End User, the Asia Pacific rapid diagnostics market consists of Hospitals and Clinics, Laboratories, Individuals/Homecare, and Other End Users. Hospitals and clinics are at the forefront due to their ability to manage high patient volumes and the need for precise, rapid diagnostics for various health concerns. Laboratories, both centralized and decentralized, remain crucial for confirmatory and high-throughput testing, particularly in urban areas. The sector for Individuals and homecare is expanding quickly, spurred by the demand for self-testing kits and remote health monitoring solutions. This trend is bolstered by e-commerce platforms, greater health awareness, and advancements in user-friendly diagnostics. Other end users, such as military organizations, academic institutions, and NGOs, also play a role in market demand through public health investigations, field operations, and humanitarian efforts. From 2021 to 2031, all segments are anticipated to grow, with homecare expected to lead due to the ongoing decentralization of healthcare services.
Make this report your own
Have queries/questions regarding a report
Take advantage of intelligence tailored to your business objective
Sikandar Kesari
Research Analyst
Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030
Aspects covered in this report
• Asia Pacific Rapid Diagnostics Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation
Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Consumables
• Analyzers/Instruments
Don't pay for what you don't need. Save 30%
Customise your report by selecting specific countries or regions
Based on Prescription, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Professional Diagnostics
• OTC Based Testing
By Platform, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Immunoassays
• Lateral Flow Assays
• Serological Assays
• Other Immunoassays
• Molecular Detection
• Polymerase Chain Reaction (PCR)
• Other Molecular Detection Tests
• Other Platforms
By Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Blood Glucose Testing
• Cardiometabolic Testing
• Infectious Disease Testing
• COVID-19 Testing
• Healthcare-associated Infections (HAI) Testing
• Hepatitis Testing
• Tropical Diseases Testing
• HIV Testing
• Influenza Testing
• Sexually Transmitted Diseases (STD) Testing
• Other Infectious Diseases Testing
• Blood Coagulation Testing
• Hematology Testing
• Cancer Testing
• Drug Abuse Testing
• Pregnancy & Fertility Testing
• Other Applications
By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Hospitals & Clinics
• Laboratories
• Individuals/Homecare
• Other End Users
The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and listing out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual report of companies, analyzing the government generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducted trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources.
Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to agriculture industry, government bodies and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.
Table of Contents
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 24
2.2 Major Growth Drivers 26
2.3 Market Restraints and Challenges 32
2.4 Emerging Opportunities and Market Trends 35
2.5 Porter’s Fiver Forces Analysis 39
3 Segmentation of Asia Pacific Market by Product 43
3.1 Market Overview by Product 43
3.2 Consumables 45
3.3 Analyzers/Instruments 46
4 Segmentation of Asia Pacific Market by Prescription 47
4.1 Market Overview by Prescription 47
4.2 Professional Diagnostics 49
4.3 OTC Based Testing 50
5 Segmentation of Asia Pacific Market by Platform 51
5.1 Market Overview by Platform 51
5.2 Immunoassays 53
5.2.1 Lateral Flow Assays 55
5.2.2 Serological Assays 56
5.2.3 Other Immunoassays 57
5.3 Molecular Detection 58
5.3.1 Polymerase Chain Reaction (PCR) 59
5.3.2 Other Molecular Detection Tests 60
5.4 Other Platforms 61
6 Segmentation of Asia Pacific Market by Application 62
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information